id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15198 R62338 |
Cohen (Carbamazepine) (Mixed indications) (Controls unexposed, NOS), 2023 | Clubfoot | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 0.48 [0.18;1.27] | -/2,674 -/4,866,362 | - | 2,674 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10176 R37269 |
Blotière (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Talipes equinovarus | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.17 [0.06;24.43] C excluded (control group) |
0/512 2/2,997 | 2 | 512 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9766 R34919 |
Blotière (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 | Talipes equinovarus | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.09 [0.07;17.49] C | 0/512 1,677/1,875,733 | 1,677 | 512 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9625 R34228 |
Källén (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 | Pes equinovarus | early pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Partial overlapping |
3.60 [0.42;30.82] C excluded (control group) |
5/1,511 1/1,084 | 6 | 1,511 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9626 R34236 |
Källén (Carbamazepine) (Controls unexposed, NOS) (Indications NOS), 2013 | Pes equinovarus | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 2.23 [0.72;5.21] | 5/1,511 2,127/1,575,847 | 2,132 | 1,511 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9653 R34361 |
Bànhidy (Carbamazepine), 2011 | Clubfoot | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 3.32 [0.12;91.61] C | 2/12 0/10 | 2 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9740 R34717 |
Van der Pol (Carbamazepine) (Controls unexposed, disease free), 1991 | Talipes | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
5.19 [0.10;276.47] C excluded (control group) |
0/11 0/55 | 0 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9741 R34742 |
Van der Pol (Carbamazepine) (Controls unexposed, sick), 1991 | Talipes | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.05 [0.04;110.56] C | 0/11 0/22 | 0 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 1.15 [0.48;2.71] | 3,811 | 4,720 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Mixed indications) (Controls unexposed, NOS; 2: Carbamazepine) (Controls unexposed NOS) (Mixed indications; 3: Carbamazepine) (Controls unexposed, NOS) (Indications NOS; 4: Carbamazepine; 5: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.6594 (by Egger's regression)
slope=-0.2549 (0.8274); intercept=0.5421 (1.1124); t=0.4873; p=0.6594
excluded 9740, 9625, 10176